ProText Mobility, Inc. (TXTM)
USD 0.0
(-11.11%)
USD 0.0
(-11.11%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 625.8 Thousand USD | 9.4% |
| 2022 | 572.04 Thousand USD | -57.01% |
| 2021 | 1.33 Million USD | -28.02% |
| 2020 | 1.84 Million USD | 7.32% |
| 2019 | 1.72 Million USD | -23.41% |
| 2018 | 2.24 Million USD | 17.69% |
| 2017 | 1.91 Million USD | 1.21% |
| 2016 | 1.88 Million USD | 0.0% |
| 2013 | 5.7 Million USD | 27.91% |
| 2012 | 4.45 Million USD | 53.82% |
| 2011 | 2.89 Million USD | 39.17% |
| 2010 | 2.08 Million USD | -37.18% |
| 2009 | 3.31 Million USD | -15.51% |
| 2008 | 3.92 Million USD | -0.32% |
| 2007 | 3.93 Million USD | 0.29% |
| 2006 | 3.92 Million USD | 102.46% |
| 2005 | 1.93 Million USD | 226.11% |
| 2004 | 594.61 Thousand USD | 41.04% |
| 2003 | 421.59 Thousand USD | -60.68% |
| 2002 | 1.07 Million USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 645.24 Thousand USD | 3.11% |
| 2023 Q3 | 618.09 Thousand USD | 0.83% |
| 2023 Q2 | 612.99 Thousand USD | 4.66% |
| 2023 Q1 | 585.68 Thousand USD | 2.38% |
| 2023 Q4 | 625.8 Thousand USD | 1.25% |
| 2023 FY | 625.8 Thousand USD | 9.4% |
| 2022 Q1 | 1.15 Million USD | -13.55% |
| 2022 Q4 | 572.04 Thousand USD | -46.7% |
| 2022 FY | 572.04 Thousand USD | -57.01% |
| 2022 Q3 | 1.07 Million USD | 0.0% |
| 2021 Q3 | 1.29 Million USD | -3.65% |
| 2021 FY | 1.33 Million USD | -28.02% |
| 2021 Q4 | 1.33 Million USD | 2.78% |
| 2021 Q2 | 1.34 Million USD | -22.83% |
| 2021 Q1 | 1.74 Million USD | 0.0% |
| 2020 FY | 1.84 Million USD | 7.32% |
| 2019 FY | 1.72 Million USD | -23.41% |
| 2018 FY | 2.24 Million USD | 17.69% |
| 2017 FY | 1.91 Million USD | 1.21% |
| 2016 FY | 1.88 Million USD | 0.0% |
| 2014 Q3 | 6.57 Million USD | 0.67% |
| 2014 Q1 | 6.02 Million USD | 5.61% |
| 2014 Q2 | 6.53 Million USD | 8.5% |
| 2013 Q3 | 5.44 Million USD | 9.67% |
| 2013 FY | 5.7 Million USD | 27.91% |
| 2013 Q1 | 4.72 Million USD | 5.92% |
| 2013 Q4 | 5.7 Million USD | 4.75% |
| 2013 Q2 | 4.96 Million USD | 5.11% |
| 2012 FY | 4.45 Million USD | 53.82% |
| 2012 Q4 | 4.45 Million USD | 11.75% |
| 2012 Q3 | 3.98 Million USD | 9.47% |
| 2012 Q2 | 3.64 Million USD | 12.0% |
| 2012 Q1 | 3.25 Million USD | 12.27% |
| 2011 FY | 2.89 Million USD | 39.17% |
| 2011 Q4 | 2.89 Million USD | 26.48% |
| 2011 Q3 | 2.29 Million USD | 23.99% |
| 2011 Q2 | 1.84 Million USD | 22.4% |
| 2011 Q1 | 1.51 Million USD | -27.5% |
| 2010 FY | 2.08 Million USD | -37.18% |
| 2010 Q1 | 3.52 Million USD | 6.44% |
| 2010 Q2 | 2.67 Million USD | -24.22% |
| 2010 Q3 | 2.57 Million USD | -3.81% |
| 2010 Q4 | 2.08 Million USD | -19.04% |
| 2009 Q3 | 3.65 Million USD | -23.83% |
| 2009 FY | 3.31 Million USD | -15.51% |
| 2009 Q4 | 3.31 Million USD | -9.18% |
| 2009 Q2 | 4.79 Million USD | 12.24% |
| 2009 Q1 | 4.27 Million USD | 8.82% |
| 2008 Q4 | 3.92 Million USD | 11.95% |
| 2008 Q2 | 3.39 Million USD | 15.82% |
| 2008 Q1 | 2.93 Million USD | -25.5% |
| 2008 FY | 3.92 Million USD | -0.32% |
| 2008 Q3 | 3.5 Million USD | 3.18% |
| 2007 Q2 | 4.17 Million USD | 8.58% |
| 2007 Q1 | 3.84 Million USD | -1.97% |
| 2007 FY | 3.93 Million USD | 0.29% |
| 2007 Q4 | 3.93 Million USD | -0.23% |
| 2007 Q3 | 3.94 Million USD | -5.56% |
| 2006 Q3 | 3.2 Million USD | 29.29% |
| 2006 FY | 3.92 Million USD | 102.46% |
| 2006 Q2 | 2.47 Million USD | -6.03% |
| 2006 Q1 | 2.63 Million USD | 36.04% |
| 2006 Q4 | 3.92 Million USD | 22.48% |
| 2005 Q3 | 1.58 Million USD | -9.64% |
| 2005 Q1 | 809.57 Thousand USD | 36.15% |
| 2005 FY | 1.93 Million USD | 226.11% |
| 2005 Q4 | 1.93 Million USD | 22.09% |
| 2005 Q2 | 1.75 Million USD | 117.11% |
| 2004 Q4 | 594.61 Thousand USD | 23.5% |
| 2004 Q2 | 548.21 Thousand USD | 69.38% |
| 2004 Q1 | 323.65 Thousand USD | -23.23% |
| 2004 FY | 594.61 Thousand USD | 41.04% |
| 2004 Q3 | 481.45 Thousand USD | -12.18% |
| 2003 FY | 421.59 Thousand USD | -60.68% |
| 2003 Q2 | 976.65 Thousand USD | 1.43% |
| 2003 Q4 | 421.59 Thousand USD | 13.7% |
| 2003 Q3 | 370.79 Thousand USD | -62.03% |
| 2003 Q1 | 962.85 Thousand USD | 0.0% |
| 2002 FY | 1.07 Million USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | -2181.227% |
| Arch Therapeutics, Inc. | 9.46 Million USD | 93.389% |
| Evofem Biosciences, Inc. | 72.47 Million USD | 99.136% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | 22.624% |
| Rebus Holdings, Inc. | 5.24 Million USD | 88.062% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | 98.94% |
| Qrons Inc. | 1.48 Million USD | 57.963% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 1.22 Million USD | 48.964% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | 99.165% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | -1300.145% |
| Skye Bioscience, Inc. | 14.07 Million USD | 95.553% |
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | 98.826% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | 93.469% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | -48.448% |
| SQZ Biotechnologies Company | 50.03 Million USD | 98.749% |
| Intellipharmaceutics International Inc. | 12 Million USD | 94.789% |
| Propanc Biopharma, Inc. | 3.85 Million USD | 83.751% |
| Mesoblast Limited | 188.44 Million USD | 99.668% |
| Marizyme, Inc. | 26.67 Million USD | 97.654% |
| Genus plc | 485 Million USD | 99.871% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | 89.289% |
| Pharming Group N.V. | 244.07 Million USD | 99.744% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | 68.867% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | 75.13% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | 83.531% |
| ContraFect Corporation | 32.53 Million USD | 98.076% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | 68.414% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | 83.65% |
| IMV Inc. | 37.93 Million USD | 98.35% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | 94.687% |
| MultiCell Technologies, Inc. | 1617.67 USD | -38585.826% |
| ONE Bio Corp. | 27.49 Million USD | 97.724% |
| Accustem Sciences Inc. | 1.07 Million USD | 42.014% |
| RVL Pharmaceuticals plc | 77.41 Million USD | 99.192% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 2.11 Million USD | 70.412% |
| Q BioMed Inc. | 8.13 Million USD | 92.305% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | 99.245% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | 87.839% |
| Biomind Labs Inc. | 1.49 Million USD | 58.241% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | 99.473% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | 93.079% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | 96.599% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | 56.355% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | -340.416% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | -211.168% |
| Curative Biotechnology, Inc. | 5.74 Million USD | 89.108% |
| GB Sciences, Inc. | 5.41 Million USD | 88.449% |
| Alpha Cognition Inc. | 7.16 Million USD | 91.265% |
| HST Global, Inc. | 593.59 Thousand USD | -5.427% |
| CSL Limited | 18.62 Billion USD | 99.997% |
| Wesana Health Holdings Inc. | 1.25 Million USD | 50.301% |
| Halberd Corporation | 728.71 Thousand USD | 14.122% |
| Enzolytics Inc. | 365.26 Million USD | 99.829% |
| Agentix Corp. | 2.51 Million USD | 75.073% |
| Resverlogix Corp. | 67.39 Million USD | 99.071% |
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | 25.386% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 444.95 Million USD | 99.859% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | 63.488% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | 97.471% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | 94.742% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | 82.925% |
| AVAX Technologies, Inc. | 3.99 Million USD | 84.33% |
| Zenith Capital Corp. | 27.56 Thousand USD | -2169.974% |
| Genscript Biotech Corporation | 1.32 Billion USD | 99.953% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | -162.224% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | 83.242% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | 8.082% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | 76.921% |
| Kadimastem Ltd | 3.5 Million USD | 82.145% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | -835.034% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 50.26 Million USD | 98.755% |
| BioStem Technologies, Inc. | 15.9 Million USD | 96.065% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 464.69 Thousand USD | -34.67% |
| LadRx Corporation | 2.2 Million USD | 71.561% |
| Cell Source, Inc. | 15.8 Million USD | 96.041% |
| Regen BioPharma, Inc. | 5.45 Million USD | 88.533% |
| Regen BioPharma, Inc. | 5.45 Million USD | 88.533% |
| NovAccess Global Inc. | 7.86 Million USD | 92.039% |
| Affymax, Inc. | 8.87 Million USD | 92.945% |
| Itoco Inc. | 1.65 Million USD | 62.144% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | 69.496% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | 89.654% |
| Mobile Lads Corp. | 1.31 Million USD | 52.356% |
| CytoDyn Inc. | 127.89 Million USD | 99.511% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | -1397.187% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | 60.047% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | 94.334% |
| SYBLEU INC | 681.41 Thousand USD | 8.16% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | 89.744% |
| International Stem Cell Corporation | 5.27 Million USD | 88.141% |
| Bioxytran, Inc. | 3.24 Million USD | 80.741% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 4.61 Million USD | 86.446% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 40.99 Million USD | 98.473% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | 97.189% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 2.02 Million USD | 69.102% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | 88.576% |
| Neutra Corp. | 973.52 Thousand USD | 35.717% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | 97.843% |
| PureTech Health plc | 125.58 Million USD | 99.502% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | 83.343% |
| IXICO plc | 1.9 Million USD | 67.068% |
| IntelGenx Technologies Corp. | 20.52 Million USD | 96.952% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 99.394% |
| CSL Limited | 18.62 Billion USD | 99.997% |
| Cellectis S.A. | 249.36 Million USD | 99.749% |